FIGURE LEGENDS
Figure 1. Study population. FAS, full analysis set; PP, per-protocol
set.
Figure 2. Laboratory parameters of CYP3A5 expressors and non-expressors
determined during regular control visits in per-protocol set (medians
with 95% confidence interval). (A) Aspartate aminotransferase (AST),
(B) Alanine aminotransferase (ALT), (C) total bilirubin, (D) Alkaline
phosphatase (ALP).
Figure 3. Tacrolimus exposure in CYP3A5 expressors and non-expressors
determined during regular control visits in per-protocol set (medians
with 95% confidence interval). (A) trough level of tacrolimus, (B)
daily tacrolimus dose, (C) tacrolimus dose/weight, (D) dose-adjusted C0,
(E) dose/kg-adjusted C0.
Figure 4. (A) 24-hour arithmetic mean whole blood tacrolimus
concentrations (ng/mL) and standard deviation for the twice-daily and
once-daily formulations; (B) Correlation between the area under the
curve (AUC) and Cmin or Cmax in the expressor group after conversion to
once-daily extended-release tacrolimus; (C) Correlation between the area
under the curve (AUC) and Cmin or Cmax in the non-expressor group after
conversion to once-daily extended-release tacrolimus.
Figure 5. Adverse event profiles in the expressors and non-expressors
(Full Analysis Set) after conversion from twice-daily to once-daily
extended-release tacrolimus.
Table 4. Adverse events stratified according to CYP3A5 expression